Gene Therapy to Target CD19 for B-cell Malignancies is under clinical development by Alaunos Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CD19 for B-cell Malignancies’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy to Target CD19 for B-cell Malignancies overview

Gene therapy is under development for the treatment of B-cell malignancies such as acute biphenotypic leukemia including acute lymphoblastic leukemia, acute myeloblastic leukemia, non-Hodgkin's lymphoma and small lymphocytic lymphoma or chronic lymphocytic leukemia. It is administered through intravenous infusion. The therapy comprises of T cells genetically modified by DNA plasmid transduction to express a cytokine and chimeric antigen receptor (CAR) which targets CD19. It is developed based on RheoSwitch technology. RheoSwitch technology is a gene switch which enables expression of transduced genes only when the small molecule activator ligand combines with the switch components.

Alaunos Therapeutics overview

Alaunos Therapeutics formerly ZIOPHARM Oncology, is a biopharmaceutical company which provides next-generation immune therapies. The company carries out the development and commercialization of in-licensed cancer drugs. It offers controlled IL-12 which provides therapy for cold tumors by turning them hot by activating an immune response and t-cell therapy to fight blood cancers and solid tumors. Alaunos Therapeutics also offers Sleeping Beauty Technology, a clinically advanced non-viral cell therapy technology which helps in the manufacturing of genetically modified chimeric antigen receptors (CARs) and T-cell receptors (TCRs) targeting specific tumor-derived antigens. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. Alaunos Therapeutics is headquartered in Boston, Massachusetts, the US.

For a complete picture of Gene Therapy to Target CD19 for B-cell Malignancies’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.